Ignite Creation Date:
2024-05-11 @ 8:28 AM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06399679
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-06
First Post:
2024-04-30
Brief Title:
Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium
Sponsor:
Washington University School of Medicine
Organization:
Washington University School of Medicine
Study Overview
Official Title:
Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium After Initial Control With Physostigmine RIVA-AP a Randomized Placebo-controlled Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RIVA-AP
Brief Summary:
Antimuscarinic delirium AMD is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors Physostigmine is effective in reversing AMD but has a short duration of action and patient commonly experience recurrence of AMD after initial control with physostigmine
Recent case reports and small observational studies suggest that rivastigmine which has a longer duration of action than physostigmine might be useful in the treatment of AMD In order to investigate the effectiveness of rivastigmine in preventing recurrence of AMD after initial control with physostigmine the investigators propose a randomized placebo-controlled clinical trial of rivastigmine for AMD The investigators hypothesize that patients treated with rivastigmine after initial control of AMD with physostigmine will experience less recurrence of antimuscarinic delirium than those treated with placebo
Recent case reports and small observational studies suggest that rivastigmine which has a longer duration of action than physostigmine might be useful in the treatment of AMD In order to investigate the effectiveness of rivastigmine in preventing recurrence of AMD after initial control with physostigmine the investigators propose a randomized placebo-controlled clinical trial of rivastigmine for AMD The investigators hypothesize that patients treated with rivastigmine after initial control of AMD with physostigmine will experience less recurrence of antimuscarinic delirium than those treated with placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None